Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More
Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with the overall sector up 40%....
Cepheid (CPHD $31.40)-Good Entry Point For Long Term
Cepheid in Low $30's- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing the MO game with a very expensive stock. Nonetheless Cepheid is a high quality Company and a...
NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24
Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and Gilead (GILD $68.85) up 6%. Biogen Idec earnings are...
Rayno Life Sciences: Investor Election Guide from Credit Suisse
Ultimate Presidential Election Guide Click above for an interesting sector and stock review from Credit Suisse including major positions of candidates. Stocks in the Rayno Life Sciences Portfolio that were mentioned on the "Obama Victory" side include: Illumina (ILMN) and ThermoFisher (TMO) On...
Will The Biotechnology Bull Market Stimulate Venture Investing?
Notes from the BioInvestor Forum October 9-12--Biotech Investing The BioInvestor Forum held every year at this time in San Francisco is one of the premier events for emerging companies. Over 500 investors and companies attended with 7 major sessions on investing and innovation trends. Over 100...